Molecular Imaging of Newly Diagnosed Prostate Cancer

被引：4
|
作者：
Williams, Scott [1 ,2 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Radiat Oncol, 305 Grattan St, Melbourne, Vic 3000, Australia
[2] Univ Melbourne, Div Radiat Oncol, Melbourne, Vic, Australia
来源：
CANCER JOURNAL | 2020年 / 26卷 / 01期
关键词：
Positron emission tomography; prostate cancer; prostate-specific membrane antigen; POSITRON-EMISSION-TOMOGRAPHY; MEMBRANE ANTIGEN-EXPRESSION; GA-68-PSMA PET/CT; C-11-CHOLINE PET/CT; METASTASES; CARCINOMA; ACID; VALIDATION; RECURRENCE; ACCURACY;
D O I：
10.1097/PPO.0000000000000427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Positron emission tomography (PET) is a valuable imaging in evaluating many malignancies. There are various molecular imaging tracers that are currently being utilized with prostate cancer (PC). Several PET agents imaging different molecular processes in PC have reached the clinic. While all of these agents have demonstrated an advantage over conventional imaging, there are considerable differences in the performance of each in staging newly diagnosed PC. In this article, we review the current updates available of different PET tracers, with a strong focus on the emerging role of prostate-specific membrane antigen PET in the management of newly diagnosed PC.
引用
收藏
页码：43 / 47
页数：5
相关论文
共 50 条
  • [31] Distribution of prostate cancer treatment options in newly diagnosed patients
    Ham, Yeji
    Nzenza, Tatenda
    Weerasinghe, Arosha
    Bolton, Damien
    Lawrentschuk, Nathan
    Sengupta, Shomik
    BJU INTERNATIONAL, 2018, 122 : 5 - 6
  • [32] Plasma estrogens in newly diagnosed patients for prostate cancer.
    Giton, Frank
    De La Taille, Alexandre
    Allory, Yves
    Vacherot, Francis
    Cussenot, Olivier
    Abbou, Clement-Claude
    Raynaud, Jean P.
    Fiet, Jean
    JOURNAL OF UROLOGY, 2007, 177 (04): : 536 - 536
  • [33] Distribution of Prostate Cancer Treatment Options in Newly Diagnosed Patients
    Ham, Yeji
    Weerasinghe, Arosha
    Nzenza, Tatenda
    Bolton, Damien
    Lawrentschuk, Nathan
    Sengupta, Shomik
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 35 - 35
  • [34] THE PREVALENCE OF SOLID MALIGNANCIES IN MEN NEWLY DIAGNOSED WITH PROSTATE CANCER
    Teper, Ervin
    Colon, Ivan
    Blank, William
    Weiss, Jeffrey P.
    Macchia, Richard J.
    Karanikolas, Nicholas T.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 4 - 4
  • [35] Assessment of indirect costs of newly diagnosed prostate cancer patients
    Jayavedappa, Ravishankar
    Chhatre, Sumedha
    Whittington, Richard
    Wein, Alan J.
    Malkowicz, S. Bruce
    JOURNAL OF UROLOGY, 2007, 177 (04): : 97 - 97
  • [36] Towards accurate genomics for newly diagnosed metastatic prostate cancer
    Nature Cancer, 2024, 5 : 8 - 9
  • [37] Baseline staging of newly diagnosed prostate cancer: A summary of the literature
    Abuzallouf, S
    Dayes, I
    Lukka, H
    JOURNAL OF UROLOGY, 2004, 171 (06): : 2122 - 2127
  • [38] Local Radiotherapy for Patients with newly diagnosed, metastatic Prostate Cancer
    Guckenberger, Matthias
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (04) : 362 - 364
  • [39] Genomic classifiers for treatment selection in newly diagnosed prostate cancer
    Fine, Noam David
    LaPolla, Fred
    Epstein, Matthew
    Loeb, Stacy
    Dani, Hasan
    BJU INTERNATIONAL, 2019, 124 (04) : 578 - 586
  • [40] Towards accurate genomics for newly diagnosed metastatic prostate cancer
    Murtha, Andrew J.
    Wyatt, Alexander W.
    NATURE CANCER, 2024, 5 (01) : 8 - 9
12345